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Abstract
Background: Epidermal Growth Factor (EGF) is a key regulatory growth factor activating many processes relevant
to normal development and disease, affecting cell proliferation and survival. Here we use a combined approach to
study the EGF dependent transcriptome of HeLa cells by using multiple long oligonucleotide based microarray
platforms (from Agilent, Operon, and Illumina) in combination with digital gene expression profiling (DGE) with the
Illumina Genome Analyzer.
Results: By applying a procedure for cross-platform data meta-analysis based on RankProd and GlobalAncova tests,
we establish a well validated gene set with transcript levels altered after EGF treatment. We use this robust gene
list to build higher order networks of gene interaction by interconnecting associated networks, supporting and
extending the important role of the EGF signaling pathway in cancer. In addition, we find an entirely new set of
genes previously unrelated to the currently accepted EGF associated cellular functions.
Conclusions: We propose that the use of global genomic cross-validation derived from high content technologies
(microarrays or deep sequencing) can be used to generate more reliable datasets. This approach should help to
improve the confidence of downstream in silico functional inference analyses based on high content data.
Background
Epidermal growth factor (EGF) is a key growth factor
regulating cell survival. Through its binding to mem-
brane receptors of the ERBB family, EGF activates an
extensive signal transduction network that includes the
PI3K/AKT, RAS/ERK and JAK/STAT pathways [1,2].
All these pathways predominantly lead to activation or
inhibition of transcription factors affecting downstream
mRNA transcription and regulating expression of both
pro- and anti-apoptotic proteins, effectively blocking the
apoptotic pathway. EGF-dependent signaling pathways
are often dysfunctional in cancer, and targeted therapies
that block EGF signaling have been successful in treat-
ing tumors [1,3,4].
Multiple approaches have been used to advance the
knowledge of the cross-talk between signaling pathways,
including the mapping of the complete EGF-dependent
transcriptome and attempting to integrate it to build
gene networks [5-13]. However, a comprehensive knowl-
edge of the whole set of genes regulated by EGF stimu-
lation is complicated by the fact that studies have been
performed on different cell lines under a variety of treat-
ment regimes (stimuli strength, length, timing). More
importantly, in most cases results have not been vali-
dated by alternative methods on a whole genome scale,
but only for a subset of genes. Two very thorough stu-
dies have used the HeLa cell line to establish the early
response to EGF at the protein kinase phosphorylation
level [14], and the transcriptional response profile in an
* Correspondence: LSumoy@imppc.org
1Bioinformatics and Genomics Program, Center for Genomic Regulation
(CRG) - Universitat Pompeu Fabra (UPF), Barcelona, Spain
Full list of author information is available at the end of the article
Llorens et al. BMC Genomics 2011, 12:326
http://www.biomedcentral.com/1471-2164/12/326
© 2011 Llorens et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.extended time course treatment with EGF [4,11] aimed
at investigating transcriptionally mediated feedback
mechanisms that modulate response to EGF. This
wealth of information makes HeLa cells an ideal experi-
mental model to attempt to study the mechanisms of
EGF signaling from a systems biology perspective.
Microarray studies have helped to uncover the tran-
scriptional response to many intracellular signaling
pathways that are perturbed by different drugs affecting
growth factor responses, contributing to a better under-
standing of their mechanisms of action, and potentially
leading to the identification of gene signatures corre-
lated with drug efficacy and potential side effects
[15-18]. Validation of microarray results by alternative
methods is usually performed for genes of interest in
order to distinguish true positives from the false posi-
tives expected from the inherent noise in highly multi-
plexed hybridization based technologies. The need for
validation comes from the unavoidable fact that in
microarray based hybridization assays there is always
some degree of cross-hybridization to be accounted for,
which may vary depending on the hybridization condi-
t i o n sa sw e l la ss p e c i f i cp robe properties, such as
sequence, length and GC content. The use of multiple
microarray platforms in a single study could in principle
be exploited as an alternative method to RT-PCR for
global validation of changes in gene expression [19], and
to confirm the detection changes in gene expression,
although microarrays suffer from compression artifacts
resulting in a lack of linearity relative to RT-PCR in the
magnitudes of fold change detected [20-26].
Recent developments in high throughput sequencing
show promise to overcome the limitations in the specifi-
city and dynamic range of microarrays. Next-generation
sequencing technology applied to gene expression profil-
ing, known as RNA-Seq, can in principle achieve abso-
lute quantitative measurements of transcript abundance
and determine transcript variants with unprecedented
resolution [27]. A comparative assessment of global
expression profiling through deep sequencing relative to
short oligonucleotide microarrays has already been per-
formed 28]. However, RNA-seq has whole transcript
coverage and conceptually is more related to tiling
arrays or exon arrays and requires far higher coverage.
A variation of RNA-Seq known as digital gene expres-
sion (DGE) takes advantage of the SAGE methodology
principle for sequence based expression profiling,
addressing and counting tag sequences next to restric-
tion enzyme sites [29]. DGE is very similar in the sam-
pling approach to long oligonucleotide probe microarray
hybridization, given that both techniques take short
nucleic acid target sequences to sample expression of
longer RNA molecules containing them, and both are 3’
biased because they rely on extension of cDNAs from
the polyA tail with a oligo-dT primer. Since these are
currently the two most cost effective methods for high
throughput expression studies, it is of interest to assess
the performance of a combination of both methodolo-
gies. Microarrays and DGE have already been shown to
be comparable in performance [30-35]. In the present
study we have used long oligonucleotide microarrays
and DGE global cross-validation to present a whole gen-
ome perspective of EGF-induced gene transcription and
its integration into functional cellular networks. Using
the RankProd test applied to multiple platforms, a
highly reliable and complete dataset of HeLa specific
EGF-dependent regulated genes has been generated
defining lists of genes not previously associated to EGF
signaling. By applying the recently developed GlobalAn-
cova test for pathway analysis of gene expression pro-
files, we used this dataset to gain insight into functional
aspects and to explore higher order gene regulatory net-
work relationships.
Results
Transcriptional profiling of EGF treated cells with multiple
oligonucleotide microarray platforms
Global transcriptional profiling can be used to get a
snapshot of the state of the cell in a particular condi-
tion. To evaluate the genes whose transcription was
regulated after 6 h of EGF treatment, treated and
untreated control sample pairs were analyzed with long
oligonucleotide probe based microarray platforms. In
order to generate a well-characterized set of EGF-stimu-
lated and control samples, three independent biological
replicate experiments were performed where HeLa cells
were serum-starved for 24 h and then stimulated with
EGF or left untreated, and verified to show the hallmark
signal transduction responses when exposed to EGF
(Additional file 1, Figure S1). Three pairs of EGF-stimu-
lated samples and the respective serum starved controls,
derived after 6 hours of treatment from each of the
same three independent experiments were subsequently
analyzed on Agilent, Operon and Illumina microarrays.
Normalized and raw data from these experiments are
accessible in the GEO database http://www.ncbi.nlm.nih.
gov/geo/ under accession number GSE1740.
For comparison of results across technologies we
focused on RefSeq genes with associated gene symbols.
This also simplifies functional analysis given that most
genes with known function belong to this group of bet-
ter annotated genes. Initial comparison between plat-
forms of the rates of change in gene expression
expressed as log2ratios using RefSeq remapped probe
gene symbols as common identifiers and the median
value of all probes for each gene showed a variable
degree of correlation. These platforms have 17,070
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genes, showed a strikingly low degree of overlap between
the lists of most significantly regulated genes, when
determined by applying an absolute fold change cut-off
of 1.2 and setting a false discovery rate at 5% with signifi-
cance analysis of microarrays (SAM) (Figure 1B; Addi-
tional file 2, Table S1). The reduced overlap observed is
consistent with previous reports of small intersection
between lists in similar experimental designs [21,26,36].
We then used gene set enrichment analysis as implemen-
ted in the GSEA tool [37] (which takes into account the
entire distribution of log2ratios) to increase the power of
the comparison of the results of all three platforms [36].
Our GSEA analysis showed a highly significant agree-
ment between all three platforms, since each gene set
identified by any of the three platforms was found to be
asymmetrically distributed within the remaining rank
ordered differential gene expression datasets (GSEA FDR
q-value = 0 for all comparisons) (Figure 2; Additional
file 3, Table S2). This result strongly argues in favor of all
platforms being able to detect the same underlying tran-
scriptional response behavior, while differences among
individual gene measurements make it more difficult to
detect these common properties when focusing only on
the intersection between the top significant gene lists
from the individual platforms.
Upon comparing different datasets, t-test based meth-
ods, such as SAM, are less sensitive and more prone to
give false positives than rank product-based tests [38].
In fact this may explain the low overlap obtained using
SAM derived gene lists. After proving with GSEA that
the datasets were truly comparable, the RankProd test
was applied to determine a statistically significant gene
list based on multiple platforms [39]. Given that there
are quite a few instances where data are discrepant
between platforms, we used this test to identify the
most likely result based on objective statistical criteria,
coming up with 656 upregulated and 596 downregulated
genes in response to EGF based on 3 independent
microarray platforms with an absolute median fold
change larger than 1.2 and an adjusted p-value of the
RankProd test below 0.05 (Additional file 4, Table S3).
Gross EGF-specific expression cell type specific biases
attributable to the HeLa molecular karyotype were
excluded by correlating expression data with copy num-
ber using array based competitive genomic hybridization
(Data not shown).
Digital expression profiling by high throughput tag
sequencing
The final gene lists obtained from microarray data ana-
lyses are only a partial representation of the transcrip-
tome due to the fact that the genes surveyed are
constrained to the probes present in each array, and
because the overlap in gene coverage and in differential
gene expression detection between platforms is incom-
plete. Ideally, it would be desirable to have a detailed
and comprehensive gene list of EGF-dependent genes.
The only way to extend the validation without being
limited by the probe content of each platform is to use
an open technique. For this reason we used the DGE
methodology developed by Illumina which is based on
the SAGE principle but up-scaled on the Genome Ana-
lyzer I (GA-I) next generation sequencing platform
[30-35]. We re-analyzed aliquots of total RNA from the
exact same three replicate experiments that had been
tested on microarrays: serum-starved and EGF-treated
for 6 h. On average, 9 × 10E6 raw sequences were
obtained per sample, which after running the analysis
pipeline allowed us to monitor the expression of 4.9 ×
10E6 unambiguously matching tags, corresponding to
16,350 different genes (as determined from RefSeq
unique gene symbols) (Table 1; Additional file 5,
Figure 1 Microarray interplatform analysis. (A) Overlap of unique
and named genes shared among the 3 microarray platforms used
in this study. The pool of 17070 shared genes was used for further
cross-platform analysis. The total numbers of genes for each
platform and for all platforms combined are indicated. (B) Overlap
of significantly regulated genes at 6 h after EGF treatment
considering each of the 3 microarray platforms independently.
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Page 3 of 19Figure 2 GSEA analysis on significantly regulated gene sets across microarray platforms. Profile of the Running ES Score & Positions of
Gene Set Members on the Rank Ordered List using 6 h EGF treatment data according to each of the three microarray platforms. In each panel,
the vertical black lines indicate the position of each of the genes of the tested gene set in the reference data set (ranked by average of the
three respective EGF versus control log2ratios of replicate experiments). The green curve plots the ES (enrichment score), which is the running
sum of the weighted enrichment score obtained from GSEA software. Within each queried gene set, the farther the position of a gene to the
left (red) implies a higher correlation with EGF up-regulated genes in the reference platform, and the farther to the right (blue) implies a higher
correlation with genes down-regulated upon EGF treatment in the reference platform. Studied gene sets correspond to lists of up- or down-
regulated genes in each platform at 6 h of EGF treatment. Significantly enriched data sets are defined according to GSEA default settings
(p < 0.001 and a false discovery rate (FDR) < 0.25). R.L.M = ranked list metric.
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by others to achieve over 90% coverage of the transcrip-
tome, with as high or higher sensitivity than short oligo-
nucleotide probe microarrays [33]. 16,220 of the 17,070
genes represented in every microarray platform could be
detected through DGE. 3,972 genes represented in either
of the 3 microarray platforms had no detectable mea-
sure by DGE in any of the three biological replicates,
whereas 130 detected tag sequencing targets had not
b e e na d d r e s s e db ya n yo ft h em i c r o a r r a yp l a t f o r m s
(Figure 3A). Neither SAM nor RankProd statistical ana-
lysis of differential gene expression by DGE gave any
significant genes after multiple testing correction. A
general comparison between microarrays versus deep
sequencing showed better correlation among genes that
had 32 or more counts in their tag sequences (Figure
4A). Following, we used CAT (’concordance at the top’)
plots [40] representing the changes among the propor-
tions of genes shared between gene lists ranked by fold
change as a measure of the concordance between each
of the different microarray platforms and DGE com-
pared to our reference microarray platform (Agilent,
Figure 4B). We then compared all microarrays to the
DGE dataset (DGE, Figure 4C), showing that there is a
significant degree of agreement between the three alter-
native commercial array platforms and DGE (Figures 4B
and 4C). These plots show that the concordance is high-
est between the top 100 genes and that, as we increase
the list size, the proportion of genes shared among lists
stabilizes around 45-50% between microarray platforms
and around 30% between microarrays and DGE. In part
this is explained by the fact that EGF regulates many
genes and the fold changes detected by each platform
are correlated but the exact ranking can vary a lot given
the large number of genes affected. In agreement with
this, gene set enrichment analysis showed a significant
correlation between the 3 microarray platforms and
DGE (Data not shown).
The RankProd analysis to integrate microarray and DGE
data (Figure 3B; Additional files 6 and 7, Tables S5 and
S6) allowed us to define a list of 638 upregulated and
526 downregulated RefSeq genes in response to EGF at
6 h (RankProd test adjusted p-value: p < 0.05, median
absolute fold change of all measurements: |FC|>1.2;
genes represented in any of the four platforms) (Figure 5;
Additional file 7, Table S6). The number of genes found
significant by RankProd when combining microarray
and sequencing data together is slightly lower than that
found significant by microarray only. This implies that
the vast majority of genes cross-validated by microarrays
turned out to give concordant results by DGE. Even
though the total number of genes was reduced, DGE
Table 1 Deep tag sequencing statistics
RefSeq GeneID Genscan RNAgenes total %o f
total
%o f
unamb.
Averages/
run
total reads (6 runs) 54072498 14042145 6265092 5244975 54072498 100.00% 9012083.00
unambiguous (6 runs) 24940641 3665152 779972 263786 29649551 54.83% 100.00% 4941591.83
0 mismatches 18084026 286158 5470 95713 18471367 62.30% 3078561.17
1 mismatch 3913853 1961500 102902 87180 6065435 20.46% 1010905.83
2 mismatches 2942762 1417494 671600 80893 5112749 17.24% 852124.83
ambiguous (6 runs) 15083422 4111901 240145 410907 19846375 36.70% 3307729.17
no matches (6 runs) 14042145 6265092 5244975 4570282 4570282 8.45% 761713.67
Summary statistics of the mapping of reads generated by the DGE pipeline.
Figure 3 Microarray versus DGE analysis. (A) Overlap of unique
and named genes shared among the 3 microarray platforms and
genes detected by DGE. The pool of 14645 shared genes was used
for further cross-platform analysis. The total numbers of genes for
each platform and for all platforms combined are indicated. (B)
Overlap of significantly regulated genes considering the 3
microarray platforms at 6 h after EGF treatment and the genes
found regulated after assessing significance by grouping microarray
and DGE data in a RankProd analysis. Left panels show up-regulated
genes and right panels show down-regulated genes.
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RankProd-significant regulated gene list (18 up and 10
down).
For a small collection of genes, independent experimen-
tal validation was performed using a SYBR green based
RT-qPCR assay on the exact same samples used in
microarray and ultrasequencing experiments. Some of
them were further validated in additional samples in a
time course experiment. Most of the genes analyzed by
RT-qPCR showed concordant results with all technolo-
gies used in this study (Additional file 8, Figure S2). In
order to assess linearity in each genomic analysis assay,
we plotted the log2ratio values of the subset of 28 genes
validated by RT-PCR (Figure 4D) and found that DGE
approximated best the fold change detected by RT-PCR.
It is noteworthy that while all microarray platforms had
similar specificity and sensitivity in detecting changes in
gene expression, DGE had more false positives, particu-
larly among genes represented by a low number of tags
(Additional file 9, Figure S3).
We then used multiple approaches for the functional
analysis of the genes found regulated by EGF including
GO enrichment analysis (with EASE), gene set enrich-
ment analysis (with GSEA), literature based network
inference (with Ingenuity) a n dag e n e r a lt e s ta p p l i e dt o
KEGG pathways (with GlobalAncova). Interestingly
with GSEA using literature defined genesets (c2
MSigDB subset) we were able to recover with very
high significance those defined by Amit et al [11] as
response signatures to EGF in HeLa cells at 4 (FDR
and 8 hours, the time points that are closest to ours;
data not shown). This further supports that in our
hands the system behaved as it has been described by
others.
We applied these same tools to the reduced dataset
including the overlap but also to all genes (including
t h o s et h a tw e r eo n l yr e p r e s e n t e di ns o m eo ft h ep l a t -
forms). Using this approach, we detected once again the
classical EGF pathway plus a few other related functions
such as genes known to modulate EGF signaling, non-
EGF EGFR agonists, known EGF-responsive transcrip-
tion factors, components of ERBB receptor-associated
trafficking and EGFR interacting proteins (Additional
file 10, Figure S4).
Figure 4 Correlation between microarrays and Illumina GA-I sequencing. (A) Comparison of estimated log2ratios from DGE (Y-axis) and the
mean of all microarray platforms (X-axis). We consider only genes that were interrogated using all platforms and genes with a mean number of
counts across lanes greater than 0. Genes with counts greater than 32 reads (colored red or green) or less than (black) 32 reads in at least one
sample are shown. (Red dots) Genes called differentially expressed based on DGE data at an 10% FDR by RankProd. (Green dots) Genes not
called as differentially expressed but above 32 counts. (Inset box) Correlation between technologies is higher when considering genes above the
32 count detection level (0.57) than when all genes are included (0.49). (B-C) Concordance at the top (CAT) plots of the different platforms with
the 500 top genes from a reference platform, shown for Agilent in (B) and DGE in (C). See inset box for color codes identifying each platforms
compared to the remaining platform used as reference. (D) Correlation plots with regression lines between log2ratios of the five high content
platforms measurements (Y-axis) and quantitative real time PCR results using SYBR green assays (X-axis), based on measurements for 21 genes at
the 6 h time point (see Additional file 2, Table S1).
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addition to the genes shared in common, those only
represented by a single platform or a subset of all plat-
forms. One of the most significant hits found when
using the inclusive dataset was the copper/cadmium
metallothionein metal ion homeostasis function, which
includes a few of the most differentially expressed
genes 6 hours after EGF treatment and although indi-
vidual platform analysis uncovered this pathway only
in Agilent arrays (Additional file 11, Figure S5A) we
validated these observations using RT-qPCR for 6 of
the human metallothionein family members. Results
indicate that all metallothionein genes studied but
MT1F are up-regulated after EGF treatment (Addi-
tional file 11, Figure S5B). This result went unnoticed
in an EGF time course treatment of HeLa cells [11]
performed on Affymetrix arrays also showing consis-
tent and progressive up-regulation of MT1E, MT1G,
MT1F, MT1H, MT1M, MT1X, MT1P2, MT2A (MT1A
and MT1B were not represented in the Affymetrix
U133A platform used in this other study) (Additional
file 11, Figure S5C). This may be indicative of a novel
function of EGF which may be to activate oxidative
stress protection and metal ion homeostasis through
up-regulation of most metallothionein genes. This
example shows that there may be inconsistencies in
probe design that can lead to results that are not
reproducible in other platforms and highlights the risk
of picking up results that are platform biased when
relying on just a single platform and the fact that there
is many hidden information in already published data-
sets that can be uncovered using the approaches
described in the present work.
EGF-dependent functional networks
To further investigate the global expression response to
EGF treatment as well as to study the interaction
between individual regulated genes and how they have a
coordinated role in specific signaling pathways, we used
the IPA (Ingenuity Pathway Analysis) software, using
the 1146 genes obtained by RankProd testing (adjusted
p-value: p < 0.05, median absolute fold change of all
measurements: |FC| > 1.2). Among the top molecular
and cellular categories, we observed the presence of the
most common functions related to EGF signaling such
as cell death, cell growth and proliferation [1], being
cancer the top disease. In all cases, the biological func-
tions identified have a very high overlap in gene content.
This is in agreement with the top regulated canonical
pathways described by IPA which are: cell death, cancer,
and cellular growth and proliferation. (Figure 6A and
Table 1).
The top ranked networks identified by IPA are asso-
ciated with cell death and survival, cellular proliferation,
and tissue development and function (Table 2). Net-
works 1 and 2 (Additional file 12, Figure S6) consist of
genes most of which interact directly with NF-kB and
ERK1/2. Upon EGF stimulation both proteins are acti-
vated, NF-KB is activated through the AKT pathway
and ERK1/2 is activated by MEK phosphorylation, being
the expression of these two genes themselves not regu-
lated at the transcriptional level upon EGF treatment
[1].These two highest scoring networks showed a high
degree of interconnectivity as shown through merging
(Figure 6B).
Figure 5 Top regulated genes derived from meta-analysis.
RankProd analysis of the combination of microarray and Illumina
GA-I ultrasequencing data sets. Heatmap of the top 50 up and
down-regulated genes detected in all four platforms ordered by
Median Fold Change (all have RankProd adjusted p-values < 0.0001).
IL11, IL8, PLAUR, ANXA10 and FOS were validated by RT-qPCR
showing concordant results (See Additional file 2, Table S1). The full
RankProd matrix from these experiments is accessible in Additional
file 6, Table S5. The list of all 1164 significantly regulated genes
(median |FC| > 1.2 and RankProd q-value < 0.05) is given in
Additional file 7, Table S6.
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networks would allow us to model a higher order net-
work in these interactions. In order to measure pathway
interconnectivity, the GlobalAncova method was applied
on the classical pathways (as defined in the KEGG data-
base). In this approach a global regulation score is com-
puted for each pathway taking into account the
expression values of all the genes belonging to it. Again,
this analysis indicated that many of the regulated path-
ways are not independent since they share a large num-
ber of genes (Figure 7). As expected, many pathways
related to cell growth and proliferation, cell death and
cell cycle are represented. Many of the most significant
pathways belonged to the signal transduction class and
Figure 6 Significant pathways and interactions among EGF-regulated geneset. (A) Core functional analysis of EGF-regulated genes derived
from the RankProd test clustering around canonical pathways performed using the Ingenuity Pathway Analysis software. (B) Pathway analysis
based on the Ingenuity Pathway Knowledge base. The two best ranked networks holding EGF-regulated genes derived from the RankProd test
were merged showing a unique network. Up-regulated genes are indicated in red and down-regulated genes in green. The shape of the node
denotes the main function of the protein encoded by the gene (see boxed inset). Continuous lines indicate interaction between the products of
the genes; dashed lines indicate an indirect interaction; lines with an arrow indicate that the source gene “acts on” the target gene. Regulated
genes are shown as grey boxes and non-regulated but associated with the regulation of some of these genes are shown as white nodes.
Orange lines indicate new gene relationships appearing after merging different networks.
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found significant by IPA analysis. In addition, among
disease related pathways, the top regulated ones were
mostly related to cancer, being “Pathways in cancer” the
top one with a total of 31 genes and 131 connections
(Table 3; Additional file 13, Table S7 for full GlobalAn-
cova analysis).
Discussion
EGF response gene signatures and higher order network
inference
Most of functional analyses performed on microarray
datasets are usually applied to data that were derived
from a single microarray platform, where often only
the expression of a few genes has been validated
experimentally by alternative methods, usually RT-
qPCR. In such cases, it is assumed that the measures
of hundreds to thousands of targets on an array are
‘true’ measurements. As has been noted in many stu-
dies, and as we show in the present study, a significant
percentage of probes on any single platform can show
discrepancies with results derived from probes for the
same target genes in different platforms or obtained
with an alternative technology. The MAQC landmark
multi site study focused on the ability to capture global
differences by different platforms and in intra platform
reproducibility and sensitivity, but did not address how
Table 2 Functional analysis of differentially expressed EGF responsive genes.
TOP NETWORKS
Associated Network Functions Focus Molecules Score
1. Cell Death, Embryonic Development, Renal and Urological Disease 28 45
2. Amino Acid Metabolism, Post-Translational Modification, Small Molecule Biochemistry 26 40
3. Cell Cycle, Cancer, Cardiovascular System Development and Function 24 35
4. Cellular Growth and Proliferation, Hematological System and Connective Tissue Development and Function 24 35
5. Cellular Movement, Cellular Assembly and Organization, Cell-to-Cell Signaling and Interaction 24 35
TOP BIOLOGICAL FUNCTIONS
Molecular and Cellular Functions p-value Molecules
1. Cell Death 7.41e
-19-6.45e
-04 145
2. Cell Growth and Proliferation 1.77e
-16-6.15e
-04 160
3. Cellular Movement 3.16e
-12-6.50e
-04 101
4. Cellular Development 9.85e
-11-6.28e
-04 115
5. Cell Cycle 1.23e
-10-6.63e
-04 75
Diseases and Disorders p-value Molecules
1. Cancer 1.82e
-17-6.63e
-04 193
2. Reproductive System Disease 5.14e
-15-6.57e
-04 98
3. Immunological Disease 1.09e
-10-6.63e
-04 70
4. Dermatological Disease and Conditions 1.59e
-08-3.33e
-04 61
5. Inflammatory Disease 1.59e
-08-5.61e
-04 58
List of Ingenuity Networks and Biological Functions generated by mapping the 1164 focus molecules that were differentially expressed during EGF treatment
according to RankProd.
Figure 7 Higher order network of interactions among EGF-
regulated genes. Network of genomic interactions among EGF-
regulated pathways (Holm-adjusted p-value < 0.01) as defined by
GlobalAncova using KEGG database functional annotation. Nodes
(pathways) that have at least two regulated genes (as defined by
RankProd analysis) in common with other pathways are connected
by continuous lines to these other pathways. The strength of each
pathway interconnection (i.e. the number of shared regulated
genes) is expressed by the width of the continuous lines
connecting the two nodes. The node color indicates the
interconnectivity of the nodes ranging from no connection to any
other pathway (white) to many connections with other pathways
(red). Numbers define KEGG categories as listed in Table 3.
Llorens et al. BMC Genomics 2011, 12:326
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Page 9 of 19Table 3 Functional analysis of EGF responsive pathways.
ID name genes regulated genes connections
1 05200 Pathways in cancer 265 31 139
2 04510 Focal adhesion 156 17 97
3 04660 T cell receptor signaling pathway 80 7 69
4 05215 Prostate cancer 74 7 65
5 04662 B cell receptor signaling pathway 59 6 63
6 04010 MAPK signaling pathway 203 25 62
7 05210 Colorectal cancer 55 6 61
8 05222 Small cell lung cancer 76 12 60
9 04012 ErbB signaling pathway 74 9 60
10 04722 Neurotrophin signaling pathway 104 9 60
11 05220 Chronic myeloid leukemia 64 7 59
12 04810 Regulation of actin cytoskeleton 163 14 46
13 05214 Glioma 55 5 44
14 05211 Renal cell carcinoma 58 9 44
15 05223 Non-small cell lung cancer 51 6 42
16 05142 Chagas disease 71 5 41
17 04310 Wnt signaling pathway 118 7 41
18 05219 Bladder cancer 35 5 37
19 05140 Leishmaniasis 42 4 36
20 04620 Toll-like receptor signaling pathway 59 4 36
21 04912 GnRH signaling pathway 70 6 35
22 04210 Apoptosis 74 8 32
23 04916 Melanogenesis 76 3 30
24 04630 Jak-STAT signaling pathway 94 12 27
25 05410 Hypertrophic cardiomyopathy (HCM) 60 7 27
26 05414 Dilated cardiomyopathy 65 7 27
27 04115 p53 signaling pathway 58 11 25
28 04621 NOD-like receptor signaling pathway 40 6 25
29 05412 Arrythmogenic right ventricular cardiomyopathy (ARVC) 52 6 25
30 04920 Adipocytokine signaling pathway 55 6 24
31 04120 Ubiquitin mediated proteolysis 120 15 22
32 04370 VEGF signaling pathway 57 3 21
33 04060 Cytokine-cytokine receptor interaction 132 14 18
34 04640 Hematopoietic cell lineage 43 7 16
35 04530 Tight junction 97 7 16
36 04340 Hedgehog signaling pathway 39 3 15
37 04622 RIG-I-like receptor signaling pathway 46 4 15
38 04360 Axon guidance 105 9 14
39 05217 Basal cell carcinoma 41 1 12
40 04144 Endocytosis 162 13 11
41 05014 Amyotrophic lateral sclerosis (ALS) 41 3 8
42 04350 TGF-beta signaling pathway 69 6 6
43 00561 Glycerolipid metabolism 38 4 5
44 00564 Glycerophospholipid metabolism 59 4 5
45 00600 Sphingolipid metabolism 27 4 4
46 04070 Phosphatidylinositol signaling system 66 4 4
47 00562 Inositol phosphate metabolism 50 3 3
48 00565 Ether lipid metabolism 20 1 3
49 05020 Prion diseases 22 3 3
50 04710 Circadian rhythm - mammal 20 4 2
51 00601 Glycosphingolipid biosysnthesis - lacto and neolacto series 21 2 0
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[41,42].
We have focused on generating gene lists extensively
cross-validated by different methodologies on the same
set of samples to ask a biologically relevant question at
the same time. We define a list of genes that has shown
consistent regulation by EGF in three different microar-
ray platforms as well as by DGE using next generation
sequencing of short tags. By using this high content
cross-validation based approach we are providing a large
and reliable dataset capturing the EGF-dependent tran-
scriptome in HeLa cells. This expands the previous
knowledge of this process, not only providing a robust
list including previously known target genes, but also
expanding it with a fair number of genes under EGF-
regulation that had not previously been associated to
EGF. In addition, we are able to define a large EGF
dependent gene network using the high interconnectiv-
ity observed among the minor pathways regulated by
EGF. The role of EGF/EGFR dynamic interaction net-
works has been studied recently with either computa-
tional approaches [43], or by integration of molecular
profiling, database and literature mining, mechanistic
modeling, and cell culture experiments, demonstrating
that EGF (among other growth factors) plays an impor-
tant role in communication networks regulating blood
stem cell fate decisions [44].
The 6 h EGF time point was chosen because of the
high amount of transcriptional regulation which
includes some well established sets of targets (that
allowed us to use known targets as positive controls)
and largely unknown regulatory mechanisms. The 6 h
EGF time point captures the steps following initial EGF
pathway activation of early response transcription fac-
t o r s( J U N ,F O S ,M Y C ,E G R 3 ) ,t h en e g a t i v ef e e d b a c k
regulation mediated by their post-transcriptional targets
(DUSP family of dual specificity phosphatases), the
increase in delayed response transcription factor activa-
tion (and downfall of the early response genes) and the
activation of the regulatory mechanisms that will deter-
mine the cell fate as either apoptosis (BCL10; BIRC2/3;
GADD45A/B; TNFR family receptors) or continued pro-
liferation and survival (cyclins, cycling dependent kinase
inhibitors, growth factors, cytokines).
Upon thorough functional analysis of microarray and
ultrasequencing data focused on the 6 h time point, we
were able to detect cell death, cell growth and prolifera-
tion, cellular movement and development responses to
EGF stimulation. These are the functional categories
appearing as significantly overrepresented using a range
of methods and tools with the set of genes that come
out significant in the multi-platform RankProd analysis
and that are present in all platforms. It allowed us to
c o n f i r mt h a to u rs y s t e mi sb e h a v i n ga sw o u l db ep r e -
dicted from prior knowledge. Given the robust nature of
our data, at the same time we can infer network rela-
tionships based on true changes in gene expression.
Networks result from interconnections between signal-
ing pathways. Such interconnections occur because the
same signaling component is capable of receiving signals
from multiple inputs or it can distribute its signal to dif-
ferent pathways. We have used the genes involved in
several networks as interconnecting genes to build
supra-pathway structures. A major limitation was found
in the fact that current versions of pathway databases
are not completely up to date. Many of the genes not
currently included in the classical pathways could be
added upon close inspection of the literature. While this
does not appear to affect the major pathways involved,
in any case, it reinforces them. From the 44 statistically
overrepresented pathways only 8 of them have no con-
nections with any other pathway. Keeping in mind the
limitations of the KEGG database we can conclude that
there is extensive interconnectivity between EGF-regu-
lated genes in our dataset.
The EGF signaling network includes survival pathways
and interacts at many levels with the apoptotic signaling
network, being able to influence on the apoptotic poten-
tial of cells modulating and regulating the balance
between survival and death. A thorough understanding
of the genes that can be modulated by EGF and all the
interactions is critical for success on rationally designed
cancer treatments. We observed a clear cross-talk
between the EGF anti-apoptotic pathways and the apop-
totic pathways. EGF signaling leads to the up-regulation
of anti-apoptotic proteins, blocking the extrinsic (death
receptors) and intrinsic (mitochondrial) pathways or
inactivating of pro-apoptotic proteins. Interestingly,
Table 3 Functional analysis of EGF responsive pathways. (Continued)
52 00532 Glycosaminoglycan biosynthesis - chondroitin sulphate 17 2 0
53 00760 Nicotinate and nicotinamide metabolism 17 4 0
54 00750 Vitamin B6 metabolism 5 1 0
55 00790 Folate biosynthesis 9 0 0
List of GlobalAncova derived differentially expressed KEGG functions upon EGF treatment indicating the total number of genes, the number of regulated genes
and the number of connections (shared regulated genes) to other pathways. The number identifying each KEGG category are the same used for the nodes in the
graph on Figure 7.
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interconnected among themselves and with signaling
pathways involved in cancer including Wnt, TGF-beta,
MAPK, p53 and other.
Hubs are proteins interacting with many partners and
its study is becoming of great interest. Essential proteins
tend to belong to biological processes that are densely
interconnected and are more likely to be hubs [45].
Interestingly, in our IPA analysis we find three main
hubs linking many regulated gene networks: ERK/
MAPK, NFKB and PI3K. While the mRNA levels of the
genes encoding for the hub proteins themselves are not
affected by EGF, we can detect strong changes in many
of the genes directly connecting to them and a high
interconnectivity among regulated genes pertaining to
each hub’s own network.
Novel gene functions regulated by EGF
As pointed out, most of the genes found to be regulated
by EGF were related to already known functions such as
cell cycle, differentiation or apoptosis, which were
detected as significant even when looking at the most
conservative gene lists obtained by combining all plat-
forms together.
Being less conservative, one can attempt to look at the
global picture of EGF response by not only looking at
the common intersection of genes represented in all
platforms, but at the union of all the identifiers. Using
this approach to try to uncover novel functionalities, it
was interesting to detect regulation of additional genes
in categories described to modulate EGF signaling (such
as DUSP dual specificity phosphatases, SOCS suppres-
sors of cytokine signaling, ERRFI1 and LRIG) [46], most
non-EGF EGFR agonists (TGF-alpha, epiregulin,
amphiregulin, HB-EGF and epigen) and the CXCL1/2/3
cytokines, which interestingly are cytogenetically linked
to a cluster of EGF family members on human 4q13.3
along with IL8 and are found to be co-regulated. In
addition, there are changes found in mRNA levels of
transcription factors of the early response and delayed
early response class [11], some of the components of
ERBB receptor endocytosis and intracellular trafficking
complexes [47] and EGFR interacting proteins [48]. This
observation supports the existence of tight feedback
mechanisms 6 h after exposure to the EGF ligand. The
purpose of these would be to shutdown EGF dependent
signaling through transcriptional up-regulation of inhibi-
tors, in agreement with the results of Amit et al [11],
along with the parallel compensatory up-regulation of
other growth factors that act through the same ERBB
receptor family.
In the attempt to uncover additional new functions on
the conserved dataset and extended datasets using several
approaches, we detected a significant overrepresentation
of metallothionein genes regulated 6 hours after EGF
treatment, both as the cadmium and copper ion homeos-
tasis functional category and the 16q13 cytogenetic band
by enrichment analysis. Metallothioneins are known to
be regulated by many stimuli such as oxidative stress,
metal ions and glucocorticoids. Indeed, the putative role
of metallothioneins in carcinogenesis has been proposed
recently [49].Our work highlights their regulation by
EGF, not yet reported to date.
It remains to be seen whether this regulation is a
direct result of transcriptional activation by EGF pri-
mary targets. Indeed, the presence of AP-1 elements in
the metallothionein promoter would provide a likely
mechanism of activation by EGF-dependent early
response genes.
Contribution to cross-platform validation
Often, studies using multiple platforms have been car-
ried out on highly heterogeneous samples with very
divergent expression profiles and on a limited number
of platforms, focusing on the common top regulated
genes, excluding the non-overlapping, and therefore
missing potentially relevant regulated genes [50].
Because the measures of gene expression themselves
cannot be directly compared among different platforms
[51], we found that the use of rank comparison tests
can serve as a way to increase the number of regulated
genes given that similarities in gene regulation are made
less dependent on the magnitude of change or the gene
expression measures themselves. Our datasets reveal
overall agreement for many genes surveyed, yet there
are quite a large number of probes that give discrepant
results. We performed an outlier analysis and were able
to detect the highest degree of disagreement (comparing
each microarray platform to the rest) in Operon, fol-
lowed by Illumina and Agilent (Data not shown). In our
metallothionein example, it was evident that the major
differences came from the subset of the genome repre-
sented on each platform. It is worth to note that effec-
tively remapping of all the probes in different platforms
indicated that there is a considerable number of probes
that do not match RefSeq transcripts (data not shown).
Stringent reanalysis of published data using these plat-
forms should take this into consideration. In addition,
we find that many probes have ambiguous matches in
other transcripts, indicating them as likely mediators of
cross-hybridization artifacts.
Assessment of DGE performance compared to
microarrays
Our basic analysis of the data generated in this work
indicates that DGE methodology is quite sensitive but
noisier than microarrays themselves. Previous reports
that have shown improved performance of DGE over
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nucleotide probe platforms such as Affymetrix, and have
used larger numbers of reads effectively increasing
dynamic range and sensitivity at a higher cost per sam-
ple [33]. There appear to be many challenges to be
solved to correct for this noise: first, there are many
more differences found in the number of tags for speci-
fic genes in biological replicates of the same conditions
than would be expected from our microarray experi-
ments; second, the normalization applied, referring to
the total number of counts, may not be the best method
(as with microarray data, more sophisticated methods
may be required). Our end result was the finding of
higher fold changes accompanied by poorer reproduci-
bility among biological replicates in DGE data relative to
microarrays. This, for the moment, makes this DGE
method not optimal to be taken as golden standard,
pointing to the need to improve the technology or have
some other means of experimental cross-validation as
we reported in this study. In this sense, while adding
RT-qPCR data on a few genes may still be sufficient for
publication under current standards, our microarray
experiments would support that global validation to
confirm larger sets of genes may be more appropriate,
especially when gene lists derived from these studies are
exploited for data integration and systems modeling.
One unexpected finding was the considerable number
of genes not detected by DGE that were detected using
microarrays. This absence of tag detection could in part
be explained by the lack of restriction sites that would
prevent these sequences from being represented in the
libraries generated in the DGE assay. Consistent with
this possibility 1.5% of the tags from DGE for which no
log2ratio could be computed in any of the three biologi-
cal replicates due to absence or too low number of tags,
actually lacked DpnII sites.
Most tags only detected by DGE (99.73%, correspond-
ing to the 1488 transcripts), had DpnII restriction sites
mapped in their RefSeq database sequence. These are
transcripts not represented in any of the three microar-
ray platforms, but this fact does not necessarily argue in
favor of DGE being more sensitive.
Our ability to compare up to four different platforms
allows us to attempt to provide tools for identifying sub-
optimal probes in each of several commonly used long
oligonucleotide microarray platforms. We have gener-
ated extensively cross-validated benchmark datasets that
can be used to fine tune analysis algorithms both for
long oligonucleotide microarray and short-read, tag-
based gene expression data.
Conclusions
In our analysis using three long oligonucleotide microar-
rays platforms and digital gene expression we explored
in depth the transcriptional response to the well-estab-
lished EGF-dependent signal transduction pathway.
Knowing that there are biases in genomic studies that
are platform dependent, our study attempted to get
around this limitation to increase the confidence in the
transcriptome changes detected, in order to allow more
reliable analyses at the functional genomics level and to
try to infer more robust networks of co-regulated genes
which may benefit further genomic studies with the
obtained datasets.
Performance comparison between microarray and next
generation based digital expression profiling suggests
that the two methodologies combined may survey the
transcriptome in a better way than each on its own, and
therefore generate more reliable datasets and uncovering
additional new functions. Ongoing improvements in
data quality and increased output of Illumina sequen-
cing technology make it possible to achieve higher read
depth and less noise at a reduced cost, which would
make DGE today even more attractive as a tool for
studying gene expression. Even though currently RNA-
seq is the most comprehensive methodological approach
to assess transcript abundance and complexity, DGE is
conceptually more comparable to microarrays. There-
fore, we believe DGE is the ideal complementary techni-
que for global cross-validation of long oligonucleotide
microarray data applied to quantitative expression
profiling.
Indeed, this approach, where data from both technolo-
gies is integrated through RankProd analysis, is capable
of detecting new genes that may previously have gone
unnoticed acting downstream of EGF and that had not
been described at a global level before. For the metal-
lothionein family this has relevance for cancer studies
since these are genes often deregulated in cancer and
that may be important in relationship to cancer resis-
tance to chemotherapy. We propose that cross-valida-
tion technologies may be exported to the desired
paradigm with the same advantages as the described in
this paper.
Methods
Reagents & Antibodies
EGF from murine submaxillary gland and anti Tubulin
(1:10000) were purchased from Sigma. Anti p-ERK1/2
(1:2000), Anti p-p90rsk (1:2000), anti p-EGFR (1:1000),
anti p27 Kip1 (1:1000) and anti p-CREB (1:2000) were
from Cell Signaling. Anti Cyclin D1 and anti cyclin E
were from Santa Cruz. U0126 and AG1478 were from
Calbiochem.
Cell Culture and Sample preparation
HeLa cells were cultured at 37°C in a 95/5 Air/CO2
water saturated atmosphere in Dulbecco’sm o d i f i e d
Llorens et al. BMC Genomics 2011, 12:326
http://www.biomedcentral.com/1471-2164/12/326
Page 13 of 19Eagle’s medium (DMEM) containing 10% heat inacti-
vated fetal bovine serum (FBS), 2 mM L-glutamine and
100 U/ml Penicillin/streptomycin. For treatments, the
cells were transferred to 60 mm dishes and, after 48 h,
starved for 24 h in DMEM containing 2% FBS. The cells
were incubated (if indicated) with the protein kinase
inhibitors U0126 (10 μM) or AG1478 (10 μM) for 30
min, and then stimulated with EGF (150 ng/ml) for the
indicated times. Cells were harvested, washed twice with
cold phosphate-buffered saline and lysed with either 2 ×
Laemmli sample buffer (Sigma), for protein extraction,
or RNeasy RLT lysis buffer (Qiagen), for total RNA
extraction.
Total RNA was quantified with a NanoDrop ND-1000
spectrophotometer followed by quality assessment with
the 2100 Bioanalyzer (Agilent Technologies) according
to the manufacturer’s instructions. Acceptable quality
values were in the 1.8-2.2 range for A260/A280 ratios,
>0.9 for rRNA ratio (28S/18S) and >8.0 for RIN (RNA
Integrity Number).
Western Blot
For Western blotting 50 μg of cell extracts from HeLa
cells were subjected to 8-10% SDS-PAGE. Gels were
transferred onto PVDF membranes and processed for
specific immunodetection by ECL using the antibodies
at the dilutions indicated above.
RT-qPCR
Quantitative real time PCR was performed on two sets
of genes. The first set was validated on the original
three biological replicate experiments analyzed by
microarrays and DGE (set 1: DUSP1, DUSP6, IL8,
C C N D 1 ,C C N E 2 ,M Y C ,F O S ,C D K N 1 A ,C D K N 1 B ,
CDKN1C, MAP3K6, IL11, EGFR, AURKC, E2F1, TGFA,
CEBPD) and the second set on three independent biolo-
gical replicates (set 2: MT1E, MT1F, MT1G, MT1H,
MT1X, MT2A). Total RNA was extracted from HeLa
cells, for set 1, with mirVana isolation kit (Ambion) and,
for set 2, with miRNeasy Mini kit (Qiagen) following the
respective manufacturer’s instructions. Purified RNAs
were treated with RNase-free DNAse (DNA-free,
Ambion) and reverse-transcribed, for set 1, with Super-
script II (Invitrogen) and, for set 2, Omniscript (Qiagen)
to generate the corresponding cDNAs that served as
PCR templates for mRNA quantification. Primers used
in this study for RT-qPCR validation can be found on
Additional file 14, Table S8.
PCR amplification and detection were performed with
the ROCHE LightCycler 480 detector, using 2 × SYBR
GREEN Master Mix (Roche) as reagent and oligonucleo-
tide primers (0.25 uM or 0.3 μM of each primer, for set
1 and set 2 respectively) following the manufacturer’s
instructions. The reaction profile had a denaturation-
activation cycle (95°C for 10 min) followed by 40 cycles
of denaturation-annealing-extension (for set 1: 95°C for
15 sec, 60°C for 40 sec, 72°C for 5 sec and, for set 2: 95°
C for 10 sec, 60°C for 10 sec, 72°C for 12 sec). Each
sample was run in duplicate. mRNA levels were calcu-
lated using the LightCycler 480 software. The mRNA
levels of each target gene and the housekeeping gene
SF3A, were determined for each sample. PCR amplifica-
tion efficiencies for all target genes and the housekeep-
i n gg e n ew e r ed e t e r m i n e du s i n gc D N Ad i l u t i o n s .T h e
relative expression ratio was calculated for set 1 using
the delta-delta-Ct method and for set 2 applying a
mathematical model incorporating the PCR efficiencies
and the crossing point deviation of EGF-treated HeLa
cells- versus control non treated cells at each time point.
Microarrays
Agilent
RNA (500 ng) was labeled using Agilent’sL o wI n p u t
RNA Labeling Kit, which involves reverse transcribing
the mRNA in the presence of T7-oligo-dT primer to
produce cDNA and then in vitro transcribing with T7
RNA polymerase in the presence of Cy3-CTP or Cy5-
CTP to produce labeled cRNA. The labeled cRNA of
the EGF-treated and the control samples from each bio-
logical replicate were labeled with alternate dyes and co-
hybridized in duplicate with dye reversal to the Agilent
Human 4 × 44K 60-mer oligo microarray according to
the manufacturer’s protocol. The arrays were washed,
dried by centrifugation and scanned on an Agilent
G2565BA microarray scanner at 100% PMT and 5 μm
resolution. Dual channel Cy5 and Cy3 fluorescence data
were extracted using Genepix 6.0 (Molecular Devices)
software using the irregular spot finding feature.
Operon
Human Operon V4 37K arrays were used featuring 70-
mer probes. First and second strand cDNA were synthe-
sized from total RNA (500 ng) with the Aminoallyl Mes-
sage Amp II Kit (Ambion). cDNA was purified and in
vitro transcribed for aRNA synthesis. aRNA was purified
and coupled to the Cy ester, and further purified, to
remove unincorporated dye. Arrays were hybridized
with dye swapping as in Agilent arrays, washed and
dried following Operon’si n s t r u c t i o n so naM a u ih y b r i -
dization station and scanned on an Agilent G2565BA
microarray scanner under at 100% PMT and 10 μm
resolution. Dual channel Cy5 and Cy3 fluorescence data
were extracted using Genepix 6.0 (Molecular Devices)
software using the irregular spot finding feature.
Illumina
Biotinylated cRNA was prepared using the Illumina
RNA Amplification Kit (Ambion) according to the man-
ufacturer’s instructions starting with from 200 ng total
RNA from each sample. cRNA was purified and each
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mina Human WG-6 V 2.0 Expression BeadChips follow-
ing the manufacturer’s instructions. After 16 h of
hybridization arrays were washed, dried, stained with
Cy3-Streptavidin and scanned using Illumina BeadScan
software on the Illumina BeadArray scanning system.
Single channel Cy3 fluorescence data were extracted
using BeadStudio data analysis software with default
settings.
Digital gene expression (DGE) profiling by high
throughput tag sequencing
For each sample, 2 μg of total RNA were used following
Illumina’s protocol for sequencing of DGE tags. Briefly,
libraries of cDNA fragments were generated by captur-
ing transcripts on oligo-dT beads, followed by synthesis
of first and second strand cDNA in situ. Cleavage with
DpnII resulted in recovery of the most 3’ portion of the
cDNA molecules, still attached to beads. A 5’ adaptor
containing a cut site for the type II restriction endonu-
clease MmeI was ligated to the cDNA. Cleavage with
MmeI released fragments of 17-18 bp from the beads.
Following 3’ adapter ligation, the resulting library was
enriched by PCR amplification (15 cycles), and purified
by PAGE. Sequencing by synthesis was carried out on
the Genome Analyzer I (Illumina), as recommended by
the manufacturer, for 36 cycles.
Raw data were processed using the Illumina pipeline
version 1.3.0. 3’ adapters were recognized and trimmed
using a script that penalizes mismatches to a lesser
extent at read ends, following the distribution of
sequencing errors along Illumina DGE reads [52]. Sev-
eral datasets of reference sequences (RefSeq, GeneID
predictions, GenScan predictions, RNAgenes) were
reduced in complexity by in silico identification of
DpnII cut sites and retrieval of these sequences plus 36
nt flanks on either side. The final mapping step was per-
formed by applying Eland iteratively in order to include
all possible product sizes, allowing up to 2 mismatches.
The compiled collection of expression tags with
removed adapters was initially aligned against the
reduced-complexity set of RefSeq entries and the targets
reference sequences were filtered as in the microarray
probe mapping to exclude any targets corresponding to
different gene symbols or with no associated gene sym-
bol. Reads mapping unambiguously were counted for
each unique transcript within the reduced-complexity
RefSeq reference set. Raw transcript counts were first
filtered by removal of RefSeq probes with values smaller
than ‘mean minus standard error’ in at least 90% of the
samples, where ‘mean = average counts of RefSeq
probes corresponding to the same gene within one sam-
ple’ and ‘standard error = standard error of counts of
RefSeq probes corresponding to the same gene within
one sample’. Subsequently, counts were normalized by
making sample-wise total numbers of reads equal to the
median total number of reads for all samples. Finally,
normalized counts of RefSeq probes corresponding to
t h es a m eg e n e( d e f i n e db yg e n es y m b o l )w e r es u m m e d
up.
Cross-mapping between platforms
For the purpose of the comparison and to have consis-
tent up to date annotation we remapped all probes in
the different microarray platforms to assign them to
gene symbols. For each of the platforms (Agilent, Illu-
mina and Operon) sequences for each probe were
mapped to the human reference genome and RefSeq
reference transcriptome (hg18 accessed through UCSC).
Mapping was done using BLAST, BWA and BOWTIE
independently. Only unambiguously mapping probes
were selected. All ambiguous probes were discarded. Up
to 2 mismatches were allowed to consider differences in
probe sequence relative to the reference. These can ori-
ginate from the disparity of sources of sequence infor-
mation and genomic annotation used by the different
microarray manufacturers and can include natural
sequence variation as well as sequencing errors in data-
bases, or artifacts generated during probe design. When
mapping to the reference genome, annotation informa-
tion (GTF from UCSC) was used from the same genome
version to create a probe-transcript link ID. We selected
probes that could be unambiguously mapped at least
once to either the genome (where there was an anno-
tated transcript) or to the reference transcriptome, with
the main requirement being that there is an association
to an official gene symbol. Transcripts corresponding to
genes without official gene symbols were ignored.
In the case where a gene was represented by multiple
array-specific probes we took the median log2ratio value
of the corresponding probes. For the Illumina GA-I
sequencing data, counts of probes representing the same
gene were summed up before calculating log2ratio
values. We took the intersection of genes in all plat-
forms and merged the corresponding log2ratio data.
Next, we took intersections for all combinations of
three platforms, then for all combinations of two plat-
forms and, finally, the probes with no overlap between
platforms were also scored. Each time, the correspond-
ing data was appended to the existing data matrix.
H e n c ew ee n du pw i t ham a t r i xc o n t a i n i n gd a t af o r
20,322 RefSeq genes with known HUGO symbols, the
union of genes in all platforms under consideration.
Statistical Analysis
Log2ratio values were computed for all pairs of control
and EGF stimulated samples. This was also done for the
one-channel microarray platforms since samples are to
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this procedure makes one- and two-channel data
directly comparable.
Analysis for differential expression on a gene-by-gene
basis was done by SAM [53] and limma [54], including
correction for multiple testing using the False Discovery
Rate (FDR) method.
For cross-platform comparisons Gene Set Enrichment
Analysis (GSEA) [37] was applied where the gene set of
interest was defined as the list of differentially expressed
genes as derived from one platform, and its enrichment
among differentially expressed genes within the remain-
ing platforms was tested. In order to further assess com-
parability between platforms we computed CAT
(’concordance at the top’) plots as described [40].
We also aimed at defining a consensus list of regu-
lated genes using information from all platforms simul-
taneously. Since expression measures are not directly
comparable between different platforms we used the
RankProd approach [39] that is based on differential
gene expression ranks. Only genes present in all the
platforms under consideration can be included in this
analysis. Therefore we applied the RankProd analysis for
all combinations of platforms as given by the complete
merge data matrix described above. P-value adjustment
according to [55] (FDR) was then applied to the union
of all genes.
In order to explore the changes in gene expression
due to EGF stimulation from a more global point of
view, we analyzed 218 KEGG pathways [56] with the
GlobalAncova approach [57]. Only genes present in all
platforms were used for this analysis. The 196 pathways
are all available human pathways that contain at least
one of those genes. Since GlobalAncova is quite sensi-
tive, we applied a rather conservative method for multi-
ple testing correction [58]. We further explored the
pathways with adjusted p-values < 0.01 with respect to
interconnections between them. We propose a network
of pathways where an edge corresponds to an overlap of
regulated genes between the two respective pathways.
Network and pathway analysis
Ingenuity pathway analysis 3.1 software (IPA; Ingenuity
Systems) was used for evaluating the functional signifi-
cance of EGF-induced gene profiles. Specified lists of
genes identified by RankProd as being affected by EGF
were used for network generation and pathway analyses
implemented in IPA tools. HUGO official gene symbols
for the selected gene lists were uploaded into the IPA
suite, which were then mapped to the Ingenuity Path-
way Knowledge Base. The so-called focus genes were
then used for generating biological networks. A score
was generated for each network according to the fit of
the original set of significant genes. This score reflects
t h en e g a t i v el o g a r i t h mo ft h ep-value, which indicates
the likelihood for the focus genes in a network of being
found together due to random chance. Using a 99%
confidence level, scores of ≥2w e r ec o n s i d e r e ds i g n i f i -
cant. Significances for biological functions were then
assigned to each network by determining a p-value for
the enrichment of the genes in the network for such
functions compared with the whole Ingenuity Pathway
Knowledge Base as a reference set.
Additional material
Additional file 1: Figure S1. Activation of signaling pathways in
HeLa cells after EGF stimulation. Serum-starved HeLa cells were
stimulated with EGF at the indicated times in the presence or absence of
kinase inhibitors. Total cell extracts were prepared as indicated in
Materials and Methods and samples were subjected to SDS-PAGE and
immunoblotting using the indicated antibodies (A, C, D). (B) Total RNA
was prepared as indicated in Material and Methods and samples were
subjected to reverse transcription and RT-qPCR using specific primers for
the indicated genes. Experiments were carried out in triplicate and in all
cases deviation was lower than 10%. (D) Immunoblots showing ERK and
p90rsk phosphorylation on the three sets used for this study. Total ERK
was used as a loading control.
Additional file 2: Table S1. Gene lists of SAM test overlap by Venn
Diagram of 3 microarray platforms and DGE (provided as word file).
Additional file 3: Table S2. Table of cross platform GSEA
enrichment scores and significance values (provided as word file).
Additional file 4: Table S3. Table of 20192 genes analyzed by
RankProd analysis of microarray data (provided as excel file).
Additional file 5: Table S4. Table of reads generated by the DGE
pipeline for each of the runs. Summary table of read mapping
statistics generated by the DGE pipeline for each of the runs.
Additional file 6: Table S5. Table of 20322 RefSeq genes analyzed
by RankProd analysis of microarrays and DGE (provided as excel
file).
Additional file 7: Table S6. Table of 1164 genes found significant by
RankProd analysis of microarrays and tag ultrasequencing
(provided as excel file).
Additional file 8: Figure S2. Time course RT-qPCR analysis of
potential EGF-regulated mRNAs. Total RNA samples from serum-
starved HeLa cells stimulated with EGF at the indicated times (15 min to
24 h) were subjected to quantitative real-time PCR (see Methods for
details). Data represent mean fold induction of at least two independent
experiments. SFA3 was used as the reference. (A) The upper panel shows
the graphical representation. (B) RT-qPCR Fold Changes and
corresponding Fold Changes derived from the three microarray platforms
and by ultrasequencing.
Additional file 9: Figure S3. Correlation plot between DGE and
microarray log2ratio values. Comparison of estimated log2ratios from
DGE (Y-axis) and the average of all three microarray platforms (X-axis).
We consider only genes that were interrogated using all platforms and
genes with a mean number of counts across lanes greater than 0. Genes
with counts greater than 32 reads in all samples (colored red or green)
or less than 32 reads (black) in at least one sample are shown. (Red dots)
Genes called differentially expressed based on DGE data at a 10% FDR by
RankProd. (Green dots) Genes not called differentially expressed but
above 32 counts. (Inset box) Correlation between technologies is higher
when considering only genes above the 32 count detection level than
when all genes are included.
Additional file 10: Figure S4. Heat maps of genes found regulated
at 6 h after EGF treatment of HeLa cells in our study and known to
be related to EGF signaling. Some genes detected in a subset of all
platforms are also included for the sake of completion. (A) Modulators of
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Page 16 of 19EGF signaling; (B) non-EGF agonists of EGFR and cytokines linked to the
EGF family locus on chromosome 4q13.3; (C) EGF-interacting and related
proteins; (D)genes described as early and delayed early response to EGF
including DNA and RNA binding proteins; and (E) components of the
ERBB receptor endocytosis and intracellular trafficking complexes.
Additional file 11: Figure S5. Metallothionein gene expression after
EGF treatment. Log2ratio of EGF-treated versus untreated heat maps of
metallothionein gene expression after EGF treatment in (A) HeLa cells at
6 h as determined in this study using Agilent, Operon, and Illumina
microarrays, and DGE sequencing; (B) RT-qPCR for 6 metallothionein
family members, (C) metallothioneins in HeLa cells in the time course
study by Amit et al using the Affymetrix platform, without replication
(relative log2ratios obtained by log2intensity subtraction of the 0 time
point value from each time point).
Additional file 12: Figure S6. Pathway analysis based on the
Ingenuity Pathway Knowledge base. The three best ranked networks
derived from EGF-regulated genes as determined by the RankProd test
were (A) Cell Death, Embryonic Development, Renal and Urological
Disease (B) Amino Acid Metabolism, Post-Translational Modification, Small
Molecule Biochemistry and (C) Cell Cycle, Cancer, Cardiovascular System
Development and Function. Upregulated genes are indicated by red
symbols and down-regulated genes by green symbols. The shape of the
node denotes the main function of the protein encoded by the gene.
Smooth lines indicate interaction between the products of the genes;
dashed lines indicate an indirect interaction and lines with an arrow
indicate an “acts on” relationship. Regulated genes are shown as grey
boxes; non-regulated genes associated with the regulation of some of
these genes are shown as white.
Additional file 13: Table S7. Significantly regulated genes
associated to regulated KEGG cellular functions as determined by
GlobalAncova (supplied as word).
Additional file 14: Table S8. List of primers used in this study.
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